


## BCL6-IN-4

<b>Cat. No.:</b>	HY-136640		
<b>CAS No.:</b>	2253879-65-9		
<b>Molecular Formula:</b>	C <sub>25</sub> H <sub>35</sub> ClN <sub>6</sub> O <sub>3</sub>		
<b>Molecular Weight:</b>	503.04		
<b>Target:</b>	Bcl-2 Family		
<b>Pathway:</b>	Apoptosis		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 73.33 mg/mL (145.77 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
			10 mg	
<b>Preparing Stock Solutions</b>	<b>1 mM</b>	1.9879 mL	9.9396 mL	19.8791 mL
	<b>5 mM</b>	0.3976 mL	1.9879 mL	3.9758 mL
	<b>10 mM</b>	0.1988 mL	0.9940 mL	1.9879 mL
Please refer to the solubility information to select the appropriate solvent.				
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 5.5 mg/mL (10.93 mM); Suspended solution; Need ultrasonic			

### BIOLOGICAL ACTIVITY

<b>Description</b>	BCL6-IN-4 is a potent B-cell lymphoma 6 (BCL6) inhibitor with an IC <sub>50</sub> of 97 nM. BCL6-IN-4 has anti-tumor activities <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 97 nM (BCL6) <sup>[1]</sup>
<b>In Vitro</b>	BCL6-IN-4 (compound 25b) inhibits OCI-Ly1 and OCI-Ly3 cell lines growth with GI <sub>50</sub> values of 2.8 μM and 4.2 μM, respectively [1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

---

[1]. Benjamin R Bellenie, et al. Achieving In Vivo Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders. J Med Chem. 2020 Apr 23;63(8):4047-4068.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA